ID   NR4A1_RAT               Reviewed;         597 AA.
AC   P22829; Q4V8M4;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 2.
DT   02-OCT-2024, entry version 200.
DE   RecName: Full=Nuclear receptor subfamily 4 group A member 1;
DE   AltName: Full=NUR77;
DE   AltName: Full=Nerve growth factor-induced protein I-B;
DE            Short=NGFI-B;
DE   AltName: Full=Orphan nuclear receptor HMR;
GN   Name=Nr4a1; Synonyms=Hmr, Ngfib;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3272167; DOI=10.1016/0896-6273(88)90138-9;
RA   Milbrandt J.;
RT   "Nerve growth factor induces a gene homologous to the glucocorticoid
RT   receptor gene.";
RL   Neuron 1:183-188(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   CHARACTERIZATION.
RX   PubMed=8395013; DOI=10.1128/mcb.13.9.5794-5804.1993;
RA   Wilson T.E., Fahrner T.J., Milbrandt J.;
RT   "The orphan receptors NGFI-B and steroidogenic factor 1 establish monomer
RT   binding as a third paradigm of nuclear receptor-DNA interaction.";
RL   Mol. Cell. Biol. 13:5794-5804(1993).
RN   [4]
RP   DNA-BINDING REGION.
RX   PubMed=1314418; DOI=10.1126/science.1314418;
RA   Wilson T.E., Paulsen R.E., Padgett K.A., Milbrandt J.;
RT   "Participation of non-zinc finger residues in DNA binding by two nuclear
RT   orphan receptors.";
RL   Science 256:107-110(1992).
RN   [5]
RP   FUNCTION.
RX   PubMed=8473329; DOI=10.1016/s0021-9258(18)52952-5;
RA   Scearce L.M., Laz T.M., Hazel T.G., Lau L.F., Taub R.;
RT   "RNR-1, a nuclear receptor in the NGFI-B/Nur77 family that is rapidly
RT   induced in regenerating liver.";
RL   J. Biol. Chem. 268:8855-8861(1993).
RN   [6]
RP   PHOSPHORYLATION AT SER-340 AND SER-350, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS.
RX   PubMed=8227042; DOI=10.1016/s0021-9258(19)74536-0;
RA   Hirata Y., Kiuchi K., Chen H.-C., Milbrandt J., Guroff G.;
RT   "The phosphorylation and DNA binding of the DNA-binding domain of the
RT   orphan nuclear receptor NGFI-B.";
RL   J. Biol. Chem. 268:24808-24812(1993).
RN   [7] {ECO:0007744|PDB:1CIT}
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 264-351 IN COMPLEX WITH NBRE, AND
RP   COFACTOR.
RX   PubMed=10331876; DOI=10.1038/8276;
RA   Meinke G., Sigler P.B.;
RT   "DNA-binding mechanism of the monomeric orphan nuclear receptor NGFI-B.";
RL   Nat. Struct. Biol. 6:471-477(1999).
RN   [8] {ECO:0007744|PDB:1YJE}
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 354-597.
RX   PubMed=15716272; DOI=10.1074/jbc.m413175200;
RA   Flaig R., Greschik H., Peluso-Iltis C., Moras D.;
RT   "Structural basis for the cell-specific activities of the NGFI-B and the
RT   Nurr1 ligand-binding domain.";
RL   J. Biol. Chem. 280:19250-19258(2005).
CC   -!- FUNCTION: Orphan nuclear receptor. Binds the NGFI-B response element
CC       (NBRE) 5'-AAAGGTCA-3' (PubMed:10331876). Binds 9-cis-retinoic acid
CC       outside of its ligand-binding (NR LBD) domain (By similarity).
CC       Participates in energy homeostasis by sequestrating the kinase STK11 in
CC       the nucleus, thereby attenuating cytoplasmic AMPK activation (By
CC       similarity). Regulates the inflammatory response in macrophages by
CC       regulating metabolic adaptations during inflammation, including
CC       repressing the transcription of genes involved in the citric acid cycle
CC       (TCA) (By similarity). Inhibits NF-kappa-B signaling by binding to low-
CC       affinity NF-kappa-B binding sites, such as at the IL2 promoter (By
CC       similarity). May act concomitantly with NR4A2 in regulating the
CC       expression of delayed-early genes during liver regeneration
CC       (PubMed:8473329). Plays a role in the vascular response to injury (By
CC       similarity). {ECO:0000250|UniProtKB:P12813,
CC       ECO:0000250|UniProtKB:P22736, ECO:0000269|PubMed:10331876,
CC       ECO:0000269|PubMed:8473329}.
CC   -!- FUNCTION: In the cytosol, upon its detection of both bacterial
CC       lipopolysaccharide (LPS) and NBRE-containing mitochondrial DNA released
CC       by GSDMD pores during pyroptosis, it promotes non-canonical NLRP3
CC       inflammasome activation by stimulating association of NLRP3 and NEK7.
CC       {ECO:0000250|UniProtKB:P12813}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:10331876};
CC       Note=Binds 2 zinc ions. {ECO:0000269|PubMed:10331876};
CC   -!- SUBUNIT: Binds the NGFI-B response element (NBRE) as a monomer
CC       (PubMed:10331876). Binds the Nur response element (NurRE), consisting
CC       of two inverse NBRE-related octanucleotide repeats separated by 6 base-
CC       pairs, as a dimer (By similarity). Interacts (via N-terminus) with
CC       NLRP3 (via LRR repeat domain); the interaction is direct, requires
CC       binding of NR4A1/Nur77 to NBRE-containing dsDNA and lipopolysaccharide,
CC       and leads to non-canonical NLRP3 inflammasome activation (By
CC       similarity). Interacts with GADD45GIP1. Interacts with STK11 (By
CC       similarity). Interacts with IFI27 (By similarity). Heterodimer (via
CC       DNA-binding domain) with RXRA (via C-terminus); DNA-binding of the
CC       heterodimer is enhanced by 9-cis retinoic acid (By similarity).
CC       Competes for the RXRA interaction with EP300 and thereby attenuates
CC       EP300 mediated acetylation of RXRA (By similarity). Interacts with
CC       NCOA1 (By similarity). Interacts with NCOA2 (By similarity). Interacts
CC       with NCOA3 (By similarity). {ECO:0000250|UniProtKB:P12813,
CC       ECO:0000250|UniProtKB:P22736, ECO:0000269|PubMed:10331876}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305|PubMed:8227042}. Cytoplasm,
CC       cytosol {ECO:0000250|UniProtKB:P22736}. Mitochondrion
CC       {ECO:0000250|UniProtKB:P22736}. Note=Nuclear export to the cytosol is
CC       XPO1-mediated and positively regulated by IFI27. Translocation to the
CC       mitochondrion upon interaction with RXRA and upon the presence of 9-cis
CC       retinoic acid (By similarity). {ECO:0000250|UniProtKB:P22736}.
CC   -!- TISSUE SPECIFICITY: Expressed in lung, brain and superior cervical
CC       ganglia. High levels are seen in the adrenal tissue.
CC   -!- INDUCTION: By nerve growth factor and during liver regeneration.
CC   -!- DOMAIN: The NR LBD domain binds the lipid A moiety of
CC       lipopolysaccharide (LPS) in the cytosol.
CC       {ECO:0000250|UniProtKB:P12813}.
CC   -!- PTM: Phosphorylated at Ser-350 by RPS6KA1 and RPS6KA3 in response to
CC       mitogenic or stress stimuli (By similarity). Phosphorylation of Ser-350
CC       results in decrease in NBRE binding while phosphorylation of Ser-340
CC       has little effect on it. {ECO:0000250, ECO:0000269|PubMed:8227042}.
CC   -!- PTM: Acetylated by p300/CBP, acetylation increases stability.
CC       Deacetylated by HDAC1 (By similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR4
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA56770.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAH97313.2; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U17254; AAA56770.1; ALT_INIT; mRNA.
DR   EMBL; BC097313; AAH97313.2; ALT_INIT; mRNA.
DR   PIR; JQ0623; JQ0623.
DR   RefSeq; NP_077364.2; NM_024388.2.
DR   RefSeq; XP_006242418.1; XM_006242356.2.
DR   RefSeq; XP_006242420.1; XM_006242358.2.
DR   RefSeq; XP_017450619.1; XM_017595130.1.
DR   PDB; 1CIT; X-ray; 2.70 A; A=264-352.
DR   PDB; 1YJE; X-ray; 2.40 A; A=354-597.
DR   PDBsum; 1CIT; -.
DR   PDBsum; 1YJE; -.
DR   AlphaFoldDB; P22829; -.
DR   SMR; P22829; -.
DR   IntAct; P22829; 2.
DR   MINT; P22829; -.
DR   STRING; 10116.ENSRNOP00000010171; -.
DR   iPTMnet; P22829; -.
DR   PhosphoSitePlus; P22829; -.
DR   PaxDb; 10116-ENSRNOP00000010171; -.
DR   Ensembl; ENSRNOT00000010171.5; ENSRNOP00000010171.2; ENSRNOG00000007607.5.
DR   Ensembl; ENSRNOT00055050397; ENSRNOP00055041483; ENSRNOG00055029103.
DR   Ensembl; ENSRNOT00060026731; ENSRNOP00060021406; ENSRNOG00060015611.
DR   GeneID; 79240; -.
DR   KEGG; rno:79240; -.
DR   AGR; RGD:620029; -.
DR   CTD; 3164; -.
DR   RGD; 620029; Nr4a1.
DR   eggNOG; KOG4217; Eukaryota.
DR   GeneTree; ENSGT00950000183038; -.
DR   HOGENOM; CLU_007368_14_2_1; -.
DR   InParanoid; P22829; -.
DR   OMA; MEVIRKW; -.
DR   OrthoDB; 5395768at2759; -.
DR   PhylomeDB; P22829; -.
DR   TreeFam; TF315430; -.
DR   Reactome; R-RNO-198693; AKT phosphorylates targets in the nucleus.
DR   Reactome; R-RNO-383280; Nuclear Receptor transcription pathway.
DR   EvolutionaryTrace; P22829; -.
DR   PRO; PR:P22829; -.
DR   Proteomes; UP000002494; Chromosome 7.
DR   Bgee; ENSRNOG00000007607; Expressed in skeletal muscle tissue and 19 other cell types or tissues.
DR   ExpressionAtlas; P22829; baseline and differential.
DR   GO; GO:0000785; C:chromatin; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0031965; C:nuclear membrane; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0098793; C:presynapse; IEA:GOC.
DR   GO; GO:0005667; C:transcription regulator complex; ISO:RGD.
DR   GO; GO:0003677; F:DNA binding; ISO:RGD.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISO:RGD.
DR   GO; GO:0003690; F:double-stranded DNA binding; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0001530; F:lipopolysaccharide binding; ISS:UniProtKB.
DR   GO; GO:0035259; F:nuclear glucocorticoid receptor binding; IPI:UniProtKB.
DR   GO; GO:0004879; F:nuclear receptor activity; IEA:InterPro.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0043565; F:sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; ISO:RGD.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; ISO:RGD.
DR   GO; GO:0002042; P:cell migration involved in sprouting angiogenesis; ISO:RGD.
DR   GO; GO:0071376; P:cellular response to corticotropin-releasing hormone stimulus; ISS:UniProtKB.
DR   GO; GO:0044344; P:cellular response to fibroblast growth factor stimulus; ISO:RGD.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; ISO:RGD.
DR   GO; GO:0032497; P:detection of lipopolysaccharide; ISS:UniProtKB.
DR   GO; GO:0035767; P:endothelial cell chemotaxis; ISO:RGD.
DR   GO; GO:0045444; P:fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0045786; P:negative regulation of cell cycle; ISS:UniProtKB.
DR   GO; GO:0014860; P:neurotransmitter secretion involved in regulation of skeletal muscle contraction; IMP:RGD.
DR   GO; GO:0160075; P:non-canonical inflammasome complex assembly; ISS:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; ISO:RGD.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; ISO:RGD.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0061469; P:regulation of type B pancreatic cell proliferation; IMP:UniProtKB.
DR   GO; GO:0001975; P:response to amphetamine; IMP:RGD.
DR   GO; GO:0051602; P:response to electrical stimulus; IEP:RGD.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEP:RGD.
DR   GO; GO:0035914; P:skeletal muscle cell differentiation; ISO:RGD.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; ISO:RGD.
DR   CDD; cd06969; NR_DBD_NGFI-B; 1.
DR   CDD; cd07348; NR_LBD_NGFI-B; 1.
DR   Gene3D; 3.30.50.10; Erythroid Transcription Factor GATA-1, subunit A; 1.
DR   Gene3D; 1.10.565.10; Retinoid X Receptor; 1.
DR   InterPro; IPR035500; NHR-like_dom_sf.
DR   InterPro; IPR003071; NR4A1.
DR   InterPro; IPR003070; NR4A1-3.
DR   InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd.
DR   InterPro; IPR001723; Nuclear_hrmn_rcpt.
DR   InterPro; IPR001628; Znf_hrmn_rcpt.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   PANTHER; PTHR24085; NUCLEAR HORMONE RECEPTOR; 1.
DR   PANTHER; PTHR24085:SF1; NUCLEAR RECEPTOR SUBFAMILY 4 GROUP A MEMBER 1; 1.
DR   Pfam; PF00104; Hormone_recep; 1.
DR   Pfam; PF00105; zf-C4; 1.
DR   PRINTS; PR01285; HMRNUCRECPTR.
DR   PRINTS; PR01284; NUCLEARECPTR.
DR   PRINTS; PR00398; STRDHORMONER.
DR   PRINTS; PR00047; STROIDFINGER.
DR   SMART; SM00430; HOLI; 1.
DR   SMART; SM00399; ZnF_C4; 1.
DR   SUPFAM; SSF57716; Glucocorticoid receptor-like (DNA-binding domain); 1.
DR   SUPFAM; SSF48508; Nuclear receptor ligand-binding domain; 1.
DR   PROSITE; PS51843; NR_LBD; 1.
DR   PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR   PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cytoplasm; DNA-binding; Inflammatory response;
KW   Metal-binding; Mitochondrion; Nucleus; Phosphoprotein; Receptor;
KW   Reference proteome; Transcription; Transcription regulation; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..597
FT                   /note="Nuclear receptor subfamily 4 group A member 1"
FT                   /id="PRO_0000053717"
FT   DOMAIN          359..594
FT                   /note="NR LBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01189"
FT   DNA_BIND        263..338
FT                   /note="Nuclear receptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   ZN_FING         266..286
FT                   /note="NR C4-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   ZN_FING         302..326
FT                   /note="NR C4-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   REGION          1..22
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          170..465
FT                   /note="Required for nuclear import"
FT                   /evidence="ECO:0000250|UniProtKB:P22736"
FT   REGION          267..353
FT                   /note="Required for binding NBRE-containing DNA"
FT                   /evidence="ECO:0000250|UniProtKB:P12813"
FT   REGION          298..360
FT                   /note="Required for the interaction with RXRA"
FT                   /evidence="ECO:0000250|UniProtKB:P22736"
FT   REGION          341..360
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          520..543
FT                   /note="Binds lipopolysaccharide"
FT                   /evidence="ECO:0000250|UniProtKB:P12813"
FT   REGION          583..594
FT                   /note="AF-2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01189"
FT   MOD_RES         340
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:8227042"
FT   MOD_RES         350
FT                   /note="Phosphoserine; by PKA, RPS6KA1 and RPS6KA3"
FT                   /evidence="ECO:0000269|PubMed:8227042"
FT   MUTAGEN         340
FT                   /note="S->A: Loss of phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:8227042"
FT   MUTAGEN         345
FT                   /note="R->K: Decreased NBRE binding."
FT                   /evidence="ECO:0000269|PubMed:8227042"
FT   MUTAGEN         348
FT                   /note="L->V: Almost complete loss of NBRE binding."
FT                   /evidence="ECO:0000269|PubMed:8227042"
FT   MUTAGEN         350
FT                   /note="S->A: Loss of phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:8227042"
FT   STRAND          267..269
FT                   /evidence="ECO:0007829|PDB:1CIT"
FT   STRAND          275..277
FT                   /evidence="ECO:0007829|PDB:1CIT"
FT   STRAND          280..282
FT                   /evidence="ECO:0007829|PDB:1CIT"
FT   HELIX           284..296
FT                   /evidence="ECO:0007829|PDB:1CIT"
FT   STRAND          303..306
FT                   /evidence="ECO:0007829|PDB:1CIT"
FT   TURN            312..317
FT                   /evidence="ECO:0007829|PDB:1CIT"
FT   HELIX           319..328
FT                   /evidence="ECO:0007829|PDB:1CIT"
FT   HELIX           333..335
FT                   /evidence="ECO:0007829|PDB:1CIT"
FT   HELIX           339..341
FT                   /evidence="ECO:0007829|PDB:1CIT"
FT   HELIX           363..374
FT                   /evidence="ECO:0007829|PDB:1YJE"
FT   HELIX           378..380
FT                   /evidence="ECO:0007829|PDB:1YJE"
FT   HELIX           399..421
FT                   /evidence="ECO:0007829|PDB:1YJE"
FT   TURN            424..428
FT                   /evidence="ECO:0007829|PDB:1YJE"
FT   HELIX           431..453
FT                   /evidence="ECO:0007829|PDB:1YJE"
FT   TURN            456..459
FT                   /evidence="ECO:0007829|PDB:1YJE"
FT   STRAND          460..462
FT                   /evidence="ECO:0007829|PDB:1YJE"
FT   STRAND          466..470
FT                   /evidence="ECO:0007829|PDB:1YJE"
FT   HELIX           471..478
FT                   /evidence="ECO:0007829|PDB:1YJE"
FT   HELIX           481..495
FT                   /evidence="ECO:0007829|PDB:1YJE"
FT   HELIX           499..510
FT                   /evidence="ECO:0007829|PDB:1YJE"
FT   HELIX           520..540
FT                   /evidence="ECO:0007829|PDB:1YJE"
FT   HELIX           550..555
FT                   /evidence="ECO:0007829|PDB:1YJE"
FT   HELIX           558..578
FT                   /evidence="ECO:0007829|PDB:1YJE"
FT   HELIX           585..592
FT                   /evidence="ECO:0007829|PDB:1YJE"
SQ   SEQUENCE   597 AA;  64282 MW;  9CFA987112337E53 CRC64;
     MPCIQAQYGT PATSPGPRDH LTGDPLALEF SKPTMDLASP ETAPTAPATL PSFSTFMDGG
     YTGEFDTFLY QLPGTAQPCS SASSTSSSSS SATSPASASF KFEDFQVYGC YPGTLSGPLD
     ETLSSSGSDY YGSPCSAPSP PTPNFQPSQL SPWDGSFGHF SPSQTYEGLR VWTEQLPKAS
     GPPPPPTFFS FSPPTGPSPS LAQSSLKLFP APATHQLGEG ESYSVPAAFP GLAPTSPNCD
     TSGILDAPVT STKARSGSSG GSEGRCAVCG DNASCQHYGV RTCEGCKGFF KRTVQKSAKY
     ICLANKDCPV DKRRRNRCQF CRFQKCLAVG MVKEVVRTDS LKGRRGRLPS KPKQPPDASP
     TNLLTSLIRA HLDSGPNTAK LDYSKFQELV LPRFGKEDAG DVQQFYDLLS GSLDVIRKWA
     EKIPGFIELS PGDQDLLLES AFLELFILRL AYRSKPGEGK LIFCSGLVLH RLQCARGFGD
     WIDNILAFSR SLHSLGVDVP AFACLSALVL ITDRHGLQDP RRVEELQNRI ASCLKEHMAA
     VAGDPQPASC LSRLLGKLPE LRTLCTQGLQ RIFCLKLEDL VPPPPIVDKI FMDTLSF
//
